INT132161

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 2005
Last Reported 2011
Negated 5
Speculated 0
Reported most in Body
Documents 48
Total Number 50
Disease Relevance 26.55
Pain Relevance 32.32

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (MTX1)
Anatomy Link Frequency
joint 1
goblet cells 1
MTX1 (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 1981 100.00 Very High Very High Very High
methotrexate 1758 100.00 Very High Very High Very High
Adalimumab 1649 100.00 Very High Very High Very High
Etanercept 935 100.00 Very High Very High Very High
corticosteroid 64 99.90 Very High Very High Very High
Arthritis 1218 99.80 Very High Very High Very High
Infliximab 515 99.72 Very High Very High Very High
Leflunomide 48 99.14 Very High Very High Very High
psoriasis 289 98.76 Very High Very High Very High
cINOD 63 98.68 Very High Very High Very High
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 2103 100.00 Very High Very High Very High
Demyelinating Disease 109 100.00 Very High Very High Very High
Syndrome 45 100.00 Very High Very High Very High
Seronegative Spondarthritis 838 99.80 Very High Very High Very High
Urinary Tract Infection 16 99.42 Very High Very High Very High
Arthritis 294 99.38 Very High Very High Very High
Psoriasis 336 98.76 Very High Very High Very High
Toxicity 63 98.52 Very High Very High Very High
INFLAMMATION 352 98.20 Very High Very High Very High
Disease Progression 61 98.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In this study, the hypothesis that beta-casomorphin-7 may also act directly on intestinal goblet cells was investigated in vitro in rat and human intestinal mucin-producing cells (DHE and HT29-MTX) using quantitative and semiquantitative RT-PCR and ELISA.
Gene_expression (producing) of MTX in goblet cells
1) Confidence 0.58 Published 2006 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 16357059 Disease Relevance 0 Pain Relevance 0.26
Indeed, LD–MTX started to be used for the treatment of arthritis from the 1980 s; before then, MTX was used only at high doses, associated with toxicity in cancer treatment.
Gene_expression (used) of MTX associated with toxicity, methotrexate, immunotherapy of cancer and arthritis
2) Confidence 0.44 Published 2010 Journal Trends in Parasitology Section Body Doc Link PMC2927876 Disease Relevance 1.43 Pain Relevance 0.59
Different uses of MTX in humans
Gene_expression (uses) of MTX associated with methotrexate
3) Confidence 0.44 Published 2010 Journal Trends in Parasitology Section Body Doc Link PMC2927876 Disease Relevance 0.67 Pain Relevance 0.37
Of all covariates tested, weight, concomitant use of methotrexate (MTX), antibody-to-GLM status, and baseline C-reactive protein (CRP) were identified as significant covariates for the apparent clearance of GLM, and weight was a significant covariate for volume of distribution.19 Serum golimumab concentrations were lower in patients who were not taking MTX, had antibodies to golimumab, were heavier, and had higher serum levels of CRP.


Neg (not) Gene_expression (taking) of MTX associated with methotrexate
4) Confidence 0.32 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 0.26 Pain Relevance 0.24
Of all covariates tested, weight, concomitant use of methotrexate (MTX), antibody-to-GLM status, and baseline C-reactive protein (CRP) were identified as significant covariates for the apparent clearance of GLM, and weight was a significant covariate for volume of distribution.19 Serum golimumab concentrations were lower in patients who were not taking MTX, had antibodies to golimumab, were heavier, and had higher serum levels of CRP.


Gene_expression (clearance) of MTX associated with methotrexate
5) Confidence 0.32 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 0.21 Pain Relevance 0.22
Of all covariates tested, weight, concomitant use of methotrexate (MTX), antibody-to-GLM status, and baseline C-reactive protein (CRP) were identified as significant covariates for the apparent clearance of GLM, and weight was a significant covariate for volume of distribution.19 Serum golimumab concentrations were lower in patients who were not taking MTX, had antibodies to golimumab, were heavier, and had higher serum levels of CRP.


Gene_expression (status) of MTX associated with methotrexate
6) Confidence 0.32 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 0.20 Pain Relevance 0.22
antagonists in patients with early RA who had not been previously treated with MTX, such as the ERA trial of etanercept,3 the PREMIER trial of adalimumab,4 and the ASPIRE trial of infliximab.27 GLM plus MTX demonstrated greater efficacy than placebo plus MTX for most of the secondary endpoints at week 24, which included DAS28 response (75.5% for both GLM 50 mg and 100 mg + MTX versus 60.6% for placebo + MTX), DAS28 remission (38.4% GLM 50 mg and 37.7% GLM 100 mg versus 28.1% placebo + MTX), and improvement in CRP levels (57% GLM 50 mg and 63% GLM 100 mg versus 25% placebo + MTX) in the prespecified ITT population.
Gene_expression (response) of MTX associated with infliximab, antagonist, rheumatoid arthritis, adalimumab, etanercept and methotrexate
7) Confidence 0.32 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 0.16 Pain Relevance 0.92
Both primary endpoints were met.24 Both 50 mg GLM + MTX and 100 mg GLM + MTX were comparable in efficacy and achieved statistical significance for all secondary endpoints at 24 weeks including ACR50, ACR70, DAS28 (using CRP) responders, and DAS28 (CRP) remission.24 Results from this trial confirm the efficacy of GLM in patients with active RA despite MTX therapy that was observed in the phase II trial,20 and demonstrate that 50 mg GLM or 100 mg GLM administered every four weeks in combination with MTX significantly reduces signs and symptoms and improves physical function in patients with RA.
Gene_expression (therapy) of MTX associated with rheumatoid arthritis and methotrexate
8) Confidence 0.32 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 0.38 Pain Relevance 0.54
Furthermore, since anti-tocilizumab antibodies are not detected without use of MTX, the combination with MTX is not required to suppress the emergence of anti-tocilizumab antibodies as long as 8 mg/kg of tocilizumab is used.
Neg (not) Gene_expression (detected) of MTX associated with methotrexate
9) Confidence 0.32 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638601 Disease Relevance 0.28 Pain Relevance 0.52
Leflunomide is an option for patients who fail MTX or discontinue MTX because of side effects (Silverman et al 2005).


Gene_expression (discontinue) of MTX associated with leflunomide and methotrexate
10) Confidence 0.31 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727897 Disease Relevance 1.15 Pain Relevance 1.22
For MTX-naïve patients with rapidly progressive, early RA, adalimumab plus MTX showed greater radiographic efficacy than MTX monotherapy across the entire spectrum of radiographic disease progression parameters; moreover, combination therapy prevented nearly all severe radiographic progression observed with MTX alone, as early as 6 months (van der Heijde, Landewe, et al 2005).


Gene_expression (showed) of MTX associated with rheumatoid arthritis, adalimumab, methotrexate and disease progression
11) Confidence 0.31 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 0.96 Pain Relevance 1.00
For MTX-naïve patients with rapidly progressive, early RA, adalimumab plus MTX showed greater radiographic efficacy than MTX monotherapy across the entire spectrum of radiographic disease progression parameters; moreover, combination therapy prevented nearly all severe radiographic progression observed with MTX alone, as early as 6 months (van der Heijde, Landewe, et al 2005).


Gene_expression (showed) of MTX associated with rheumatoid arthritis, adalimumab, methotrexate and disease progression
12) Confidence 0.31 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 0.98 Pain Relevance 1.06
Concomitant MTX administration does not adversely affect adalimumab serum concentrations; adalimumab had an average steady-state serum concentration of 5mg/mL and 8–9 ?
Gene_expression (administration) of MTX associated with adalimumab and methotrexate
13) Confidence 0.31 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 0.50 Pain Relevance 0.79
The results of ARMADA and DE019 confirm other studies showing that TNF antagonists in combination with MTX are more effective in the relief of signs and symptoms of RA and in inhibiting radiographic progression than MTX monotherapy, even in patients with long-standing disease.


Gene_expression (progression) of MTX associated with antagonist, rheumatoid arthritis, disease and methotrexate
14) Confidence 0.31 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 0.74 Pain Relevance 0.68
For MTX-naïve patients with rapidly progressive, early RA, adalimumab plus MTX showed greater radiographic efficacy than MTX monotherapy across the entire spectrum of radiographic disease progression parameters; moreover, combination therapy prevented nearly all severe radiographic progression observed with MTX alone, as early as 6 months (van der Heijde, Landewe, et al 2005).


Gene_expression (observed) of MTX associated with rheumatoid arthritis, adalimumab, methotrexate and disease progression
15) Confidence 0.31 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 1.08 Pain Relevance 1.11
The PREMIER study was a 2-year, randomized, double-blind, active comparator-controlled trial designed to compare the efficacy and safety of adalimumab plus MTX versus adalimumab monotherapy or MTX monotherapy in 799 MTX-naïve RA patients with early (<3 years), aggressive disease (Breedveld et al 2006).
Gene_expression (monotherapy) of MTX-na associated with rheumatoid arthritis, adalimumab, disease and methotrexate
16) Confidence 0.31 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 0.57 Pain Relevance 1.02
The PREMIER study was a 2-year, randomized, double-blind, active comparator-controlled trial designed to compare the efficacy and safety of adalimumab plus MTX versus adalimumab monotherapy or MTX monotherapy in 799 MTX-naïve RA patients with early (<3 years), aggressive disease (Breedveld et al 2006).
Gene_expression (monotherapy) of MTX associated with rheumatoid arthritis, adalimumab, disease and methotrexate
17) Confidence 0.31 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 0.57 Pain Relevance 1.01
For MTX-naïve patients with rapidly progressive, early RA, adalimumab plus MTX showed greater radiographic efficacy than MTX monotherapy across the entire spectrum of radiographic disease progression parameters; moreover, combination therapy prevented nearly all severe radiographic progression observed with MTX alone, as early as 6 months (van der Heijde, Landewe, et al 2005).


Gene_expression (showed) of MTX-na associated with rheumatoid arthritis, adalimumab, methotrexate and disease progression
18) Confidence 0.31 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 0.97 Pain Relevance 1.01
The PREMIER study was a 2-year, randomized, double-blind, active comparator-controlled trial designed to compare the efficacy and safety of adalimumab plus MTX versus adalimumab monotherapy or MTX monotherapy in 799 MTX-naïve RA patients with early (<3 years), aggressive disease (Breedveld et al 2006).
Gene_expression (monotherapy) of MTX associated with rheumatoid arthritis, adalimumab, disease and methotrexate
19) Confidence 0.31 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 0.63 Pain Relevance 1.04
Patients (n=313) were stratified according to MTX use (yes or no) and extent of psoriasis involvement (?
Gene_expression (stratified) of MTX associated with psoriasis and methotrexate
20) Confidence 0.31 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 1.24 Pain Relevance 1.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox